Información del artículo
El Texto completo está disponible en PDF
References
[1.]
The author apologizes for not using multiple relevant references due to editorial restriction.
[2.]
A.F. Ayyobi, S.H. McGladdery, M.J. McNeely, M.A. Austin, A.G. Motulsky, J.D. Brunzell.
Small, dense LDL (sdLDL) and elevated apo B are the common characteristics for the 3 major lipid phenotypes of FCHL.
Arterio Thromb Vasc Biol, 23 (2003), pp. 1289-1294
[3.]
M.A. Austin, H. Horowitz, E. Wijsman, R. Krauss, J.D. Brunzell.
Bimodality of apolipoprotein B levels in familial combined hyperlipidemia.
Atheroscler, 92 (1992), pp. 67-77
[4.]
G.P. Jarvik, J.D. Brunzell, M.A. Austin, R.M. Krauss, A.G. Motulsky, E. Wijsman.
Genetic predictors of FCHL in four large pedigrees. Influence of apolipoprotein B level major locus predicted genotype and LDL subclass phenotype.
Arterioscler Thromb Vasc Biol, 14 (1994), pp. 1687-1694
[5.]
S.P. Babirak, P.-H. Iverius, W.Y. Fujimoto, J.D. Brunzell.
The detection and characterization of the heterozygote state for lipoprotein lipase deficiency.
Arteriosclerosis, 9 (1989), pp. 326-334
[6.]
S. Babirak, B.G. Brown, J.D. Brunzell.
Familial combined hyperlipidemia and abnormal lipoprotein lipase.
Arterio Thromb, 12 (1992), pp. 1176-1183
[7.]
M. Castro Cabezas, T.W. De Bruin, H.W. De Valk, C.C. Shoulders, H. Jansen, W.D. Erkelens.
Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.
J Clin Invest, 92 (1993), pp. 160-168
[8.]
J.Q. Purnell, S.E. Kahn, R.S. Schwartz, J.D. Brunzell.
Relationship of insulin sensitivity and apolipoprotein B levels to intraabdominal fat in subjects with familial combined hyperlipidemia.
Arter Thromb Vasc Biol, 21 (2001), pp. 567-572
[9.]
C. Alexander, P. Landsman, S. Teutsch, S. Haffner.
NCEP-defined metabolic syndrome, diabetes and prevalence of coronary heart disease among NHANES III participants age 50 years and older.
Diabetes, 52 (2003), pp. 1210-1214
[10.]
M.C. Carr, J.D. Brunzell.
Abdominal obesity and dyslipidemia in the metabolic syndrome: Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk.
J Clin Endocrin Metab, 89 (2004), pp. 2601-2607
[11.]
J.D. Brunzell, J.J. Albers, A. Chait, S.M. Grundy, E. Groszek, G.B. McDonald.
Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia.
J Lipid Res, 24 (1983), pp. 147-155
[12.]
M. Adiels, S.-O. Olofsson, M.-R. Taskinen, J. Boren.
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
Arter Thromb Vasc Biol, 28 (2008), pp. 1225-1236
[13.]
M.A. Austin, B. McKnight, K.L. Edwards, C.M. Bradley, M.J. McNeely, B.M. Psaty, et al.
Cardiovascular disease mortality in the familial forms of hypertriglyceridemia: A 20-year prospective study.
Circulation, 101 (2000), pp. 2777-2782
[14.]
B.G. Brown, J.J. Albers, L.D. Fisher, S.M. Schaefer, J.-T. Lin, C. Kaplan, et al.
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
N Engl J Med, 323 (1990), pp. 1289-1298
Copyright © 2010. Sociedad Española de Arteriosclerosis y Elsevier España S.L.